Loading...

180 Life Sciences Corp.

ATNF•NASDAQ
Healthcare
Biotechnology
$2.21
$-0.60(-21.35%)

180 Life Sciences Corp. (ATNF) Company Profile & Overview

Explore 180 Life Sciences Corp.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

180 Life Sciences Corp. (ATNF) Company Profile & Overview

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

SectorHealthcare
IndustryBiotechnology
CEOLloyd Blair Jordan

Contact Information

https://180lifesciences.com
650 507 0669
Building 4, Palo Alto, CA, 94306

Company Facts

4 Employees
IPO DateJun 27, 2017
CountryUS
Actively Trading

Frequently Asked Questions

;